Connect Biopharma (CNTB) Holdings announced the presentation of clinical data supporting rademikibart, the Company’s investigational, next-generation, potentially best-in-class anti-interleukin-4-receptor alpha antibody, at the European Academy of Allergy and Clinical Immunology, EAACI, 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually. Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma; Rademikibart reduced annualized exacerbations in patients with eosinophilic-driven type 2 asthma; Data supports ongoing Phase 2 acute exacerbation studies in asthma and COPD; expect to report topline data from both studies in 1H26
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTB: